Physician profile
Crystal L Jones
NPI 1215965314
$3,488.24
in general payments reported to CMS, 2019-2025
33 companies · $626 in 2025
The $626 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $71.70 · 2021: $28.56 · 2022: $966 · 2023: $637 · 2024: $951 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,214.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $679.19 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $519.19 | 2019-2025 | Tezspire, Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $265.67 | 2022-2024 | Caplyta |
| Lilly USA, LLC | $228.07 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $184.12 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $174.22 | 2019-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $159.74 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $151.58 | 2019-2024 | |
| Abbott Laboratories | $133.62 | 2022-2025 | Freestyle Libre |
| Amgen INC. | $131.12 | 2019-2023 | Otezla, Repatha |
| Radius Health, INC. | $105.84 | 2019-2025 | Tymlos |
| Lundbeck LLC | $92.36 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.92 | 2022-2023 | Jardiance |
| Dexcom, INC. | $59.93 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $56.15 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $46.29 | 2019-2024 | Vaxelis, Gardasil 9, M-M-R II |
| Eisai INC. | $41.60 | 2024-2025 | |
| Axsome Therapeutics, INC. | $37.22 | 2022-2023 | Auvelity |
| Verona Pharma, INC. | $35.64 | 2025 | Ohtuvayre |
| Medtronic, INC. | $34.13 | 2022-2024 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $33.49 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $32.77 | 2023-2024 | Rybelsus, Ozempic |
| Mylan Specialty L.P. | $28.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.42 | 2022 | |
| Kyowa Kirin, INC. | $23.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.03 | 2019 | |
| Boston Scientific Corporation | $17.68 | 2025 | Watchman Access System |
| Sumitomo Pharma America, INC. | $17.05 | 2025 | Gemtesa |
| Collegium Pharmaceutical, INC. | $16.82 | 2022 | |
| Tonix Medicines, INC. | $16.20 | 2025 | Tonmya |
| Electromed, INC. | $15.04 | 2025 | Smartvest |
| Phathom Pharmaceuticals, INC. | $14.96 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.